SC
ITCI

Sagefield Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sagefield Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,800
Closed -$1.56M – 135
2025
Q1 		$1.56M Buy
+11,800
New +$1.47M 0.19% 71

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Sagefield Capital's ITCI Position: Q2 2025 in Review

Sagefield Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 11,800 shares — an estimated $1.56M sold.

Sagefield Capital first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $1.56M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Sagefield Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Sagefield Capital sold 11,800 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.56M.
  • Sagefield Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
  • Sagefield Capital's Intra-Cellular Therapies Inc. position peaked at $1.56M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Sagefield Capital's 13F filing for Q2 2025, filed 14 Aug 2025.